Brii Biosciences Limited (2137) AI Stock Analysis

• Market Cap: €1.30B
• Dividend Yield: N/A
• Average Volume (3M): 3.60M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -100.00%
• EPS Growth: -176.44%
• Country: HK
• Employees: 98
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 732,058,500
• 10 Day Avg. Volume: 2,468,900
• 30 Day Avg. Volume: 3,596,436
• PEG Ratio: 0.03
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: HK$1.50 ▼(-17.58%Downside)

Brii Biosciences faces significant challenges, with financial performance critically hindered by profitability issues and negative cash flow trends. Technical indicators suggest bearish momentum, further impacting the stock's potential. Valuation metrics highlight unattractiveness due to ongoing losses and lack of dividends.

Brii Biosciences Limited Business Overview & Revenue Model

Company Description

Brii Biosciences Limited (2137) is a biopharmaceutical company focused on developing innovative therapies to improve public health outcomes. With a strong emphasis on infectious diseases and central nervous system (CNS) disorders, Brii Biosciences leverages cutting-edge research and development to bring novel treatments to market. The company's core products and services are centered around its pipeline of drug candidates designed to address significant unmet medical needs.

How the Company Makes Money

Brii Biosciences makes money primarily through the development and commercialization of its drug candidates. The company's revenue model includes licensing agreements, partnerships, and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of co-developed products. Key revenue streams also include government grants and funding from health organizations, which support the company's research efforts. Strategic alliances and partnerships are significant factors contributing to Brii Biosciences' earnings, as they enable the company to leverage external expertise and resources for its drug development programs.

Brii Biosciences Limited Financial Statement Overview

Summary

Brii Biosciences shows strong equity, but faces significant profitability and cash flow challenges. The company's well-capitalized status is overshadowed by ongoing operational losses and negative cash flow trends, posing potential threats to financial stability.

Income Statement

Brii Biosciences has experienced fluctuating revenue trends with a decline from 2023 to 2024. The net loss widened significantly in 2024, indicating profitability challenges. Margins such as the Gross Profit Margin remain stable at 100%, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company's balance sheet shows a strong equity position but also reveals a concerning debt-to-equity ratio due to negative equity in previous years. The equity ratio is favorable, indicating a well-capitalized company, though historical liabilities have been significant relative to assets.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which suggests challenges in generating cash from operations. The lack of operating cash flow in 2024 highlights potential liquidity risks, though substantial cash reserves provide a buffer.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.29M	56.32M	51.63M	92.54M	82.22M
Gross Profit	54.29M	56.32M	51.63M	92.54M	82.22M
EBITDA	-392.51M	-168.20M	-503.58M	-602.80M	-890.79M
Net Income	-508.16M	-174.83M	-452.63M	-4.12B	-1.21B
Balance Sheet
Total Assets	2.71B	3.20B	3.39B	3.61B	1.27B
Cash, Cash Equivalents and Short-Term Investments	2.33B	2.66B	3.00B	3.35B	1.05B
Total Debt	28.02M	3.16M	12.66M	21.62M	28.33M
Total Liabilities	100.55M	125.87M	234.35M	300.44M	3.01B
Stockholders Equity	2.66B	3.12B	3.19B	3.34B	-1.74B
Cash Flow
Free Cash Flow	-376.12M	-643.62M	-635.57M	-880.49M	-403.72M
Operating Cash Flow	-372.89M	-594.01M	-496.28M	-879.46M	-403.72M
Investing Cash Flow	895.47M	-104.35M	-1.43B	-475.76M	-43.65M
Financing Cash Flow	-9.41M	-10.98M	-3.04M	3.23B	657.00M

Brii Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Positive. The current price of 1.82 is above the 20-day moving average (MA) of 1.76, below the 50-day MA of 1.82, and above the 200-day MA of 1.50, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 53.16 is Neutral, neither overbought nor oversold. The STOCH value of 75.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2137.

Brii Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	59 Neutral	HK$15.49B	5.53	-7.44%	4.08%	11.55%	-28.15%
1875	59 Neutral	HK$1.42B	35.59	4.92%	―	38.48%	―
2126	59 Neutral	HK$1.14B	―	-41.34%	―	-10.78%	24.88%
1244	52 Neutral	HK$1.29B	―	-21.22%	―	-31.34%	67.95%
6998	51 Neutral	HK$1.26B	―	-4.30%	―	―	92.45%
2137	45 Neutral	€1.30B	―	-17.41%	―	-100.00%	-176.44%
2511	36 Underperform	HK$2.17B	―	-67.57%	―	―	54.79%

Brii Biosciences Limited Corporate Events

Brii Biosciences Partners with Joincare for BRII-693 Development in Greater China

Brii Biosciences Limited has entered into a licensing agreement with Joincare Pharmaceutical Group to develop and commercialize BRII-693, a novel antibiotic for multidrug-resistant infections, in Greater China. This partnership leverages Joincare’s expertise in manufacturing and commercialization, aiming to address the critical unmet clinical needs for hospital antibiotics in the region, thereby enhancing Brii Biosciences’ strategic positioning in the anti-infection market.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Announces AGM Results and Board Changes

Brii Biosciences Limited announced the results of its Annual General Meeting held on June 3, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements, re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors, which underscores the company’s stability and ongoing commitment to strong governance practices.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Reports Promising Phase 2 Results for HBV Treatment

Brii Biosciences Limited announced promising interim data from its Phase 2 ENSURE study, presented at the European Association for the Study of the Liver Congress 2025. The study evaluates the combination of elebsiran, an investigational siRNA, with pegylated interferon alpha (PEG-IFN α) in treating chronic hepatitis B virus (HBV) infection. Results showed that participants previously treated with BRII-179, a therapeutic vaccine, achieved faster and higher rates of hepatitis B surface antigen (HBsAg) seroclearance compared to those without prior treatment. This suggests that pre-treatment with BRII-179 may enhance immune response, potentially allowing for shorter treatment durations. The findings could significantly impact the treatment landscape for chronic HBV, offering a more effective and efficient therapeutic option for patients.

Brii Biosciences Reschedules Annual General Meeting to June 3, 2025

Brii Biosciences Limited has announced a change in the date of its Annual General Meeting (AGM), which will now be held on June 3, 2025, instead of the previously scheduled June 17, 2025. This rescheduling also affects the closure period of the register of members, which will now be closed from May 29 to June 3, 2025, to determine shareholders’ eligibility to attend and vote at the AGM. The company has clarified that all other information related to the AGM remains unchanged, and no revised documents will be issued.

Brii Biosciences Announces 2025 AGM and Key Resolutions

Brii Biosciences Limited has announced its upcoming annual general meeting (AGM) scheduled for June 3, 2025, to be held online. The AGM will address several key resolutions, including the adoption of the company’s financial statements for 2024, re-election of directors, and re-appointment of Deloitte Touche Tohmatsu as the auditor. Additionally, the meeting will consider resolutions to authorize the board to manage share allotments and other related powers, which could impact the company’s capital structure and shareholder value.